medigraphic.com
SPANISH

Acta Médica Grupo Angeles

Órgano Oficial del Hospital Angeles Health System
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Send manuscript
    • Names and affiliations of the Editorial Board
  • Policies
  • About us
    • Data sharing policy
    • Stated aims and scope
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2025, Number 2

<< Back Next >>

Acta Med 2025; 23 (2)

The usefulness of the measurement of the cutaneous silent period and sympathetic skin response in post-COVID symptomatic patients with regular neuroconduction studies

De LAA, Hernández CJ, García S, Varela BJ, Rojas NMA, Romero FLO, López PBJ, Escalante PEJ, Villagrán GAE, Hernández SCL, Palestina AKC, Salazar AID
Full text How to cite this article 10.35366/119473

DOI

DOI: 10.35366/119473
URL: https://dx.doi.org/10.35366/119473

Language: Spanish
References: 12
Page: 121-125
PDF size: 220.08 Kb.


Key words:

cutaneous silent period, sympathetic skin response, neuroconduction study, milliseconds, microvolts.

ABSTRACT

The complications observed in patients after SARS-CoV-2 infection are heterogeneous and of multiple degrees of severity, including neuropathy. There are patients with neuropathic symptoms whose conventional nerve conduction studies (NCS) are regular. Neurophysiological tests for thin nerve fibers, such as "sympathetic skin response" (SSR) and "cutaneous silent period" (CSP), likely provide information that contributes to the diagnosis of these patients.


REFERENCES

  1. Gholami M, Safari S, Ulloa L, Motaghinejad M. Neuropathies and neurological dysfunction induced by coronaviruses. J Neurovirol. 2021; 27 (3): 380-396.

  2. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A et al. Neurological associations of COVID-19. Lancet Neurol. 2020; 19 (9): 767-783.

  3. Orsucci D, Ienco EC, Nocita G, Napolitano A, Vista M. Neurological features of COVID-19 and their treatment: a review. Drugs Context. 2020; 9: 1-12.

  4. Maury A, Lyoubi A, Peiffer-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: a narrative review for clinicians. Rev Neurol (Paris). 2021; 177 (1-2): 51-64.

  5. Quattrini C, Jeziorska M, Malik RA. Small fiber neuropathy in diabetes: clinical consequence and assessment. Int J Low Extrem Wounds. 2004; 3 (1): 16-21.

  6. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008; 131 (Pt 7): 1912-1925.

  7. Low VA, Sandroni P, Fealey RD, Low PA. Detection of small-fiber neuropathy by sudomotor testing. Muscle Nerve. 2006; 34 (1): 57-61.

  8. Low PA. Laboratory evaluation of autonomic failure. In: Low PA, editor. Clinical autonomic disorders. Rochester, MN: Little, Brown; 1993. pp. 183-195.

  9. Levy DM, Reid G, Rowley DA, Abraham RR. Quantitative measures of sympathetic skin response in diabetes: relation to sudomotor and neurological function. J Neurol Neurosurg Psychiatry. 1992; 55 (10): 902-908.

  10. Bari DS, Yacoob Aldosky HY, Martinsen OG. Simultaneous measurement of electrodermal activity components correlated with age-related differences. J Biol Phys. 2020; 46 (2): 177-188.

  11. Kucera P, Goldenberg Z, Kurca E. Sympathetic skin response: review of the method and its clinical use. Bratisl Lek Listy. 2004; 105 (3): 108-116.

  12. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008; 131 (Pt 7): 1912-1925.




Table 1
Table 2
Table 3
Table 4
Table 5

2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med. 2025;23